Genomic Cancer Panel Profiling Market Size, Share and Trends Analysis, By Offering (Instruments, Kits and Reagents, Software/Bioinformatics Solutions, and Services), By Technology (NGS, ddPCR, Multiplex PCR & Microarray, and Others), By Biomarker Type, By Clinical Application, By Cancer Type, By End-Use, and By Region, Forecast 2025-2032

Genomic Cancer Panel Profiling Market Overview and Key Insights:

Genomic cancer panel profiling market size reached USD 8.87 billion in 2024 and is expected to register a revenue CAGR of 11.4% during the forecast period. A laboratory technique called genomic profiling examines the genetic material of cancer cells to find changes and mutations in hundreds of genes. This method assesses the DNA and RNA of tumors using cutting-edge instruments like next-generation sequencing (NGS), offering a comprehensive picture of their genetic landscape. Finding the genetic alterations that propel tumor growth is the goal of genomic profiling, which helps with accurate diagnosis and prognosis.

Market Drivers:

Growing burden of cancer globally is a key driver of revenue growth in genomic cancer panel profiling market. According to the American Cancer Society, in the United States, approximately 20,890 women will be diagnosed with ovarian cancer in 2025, with approximately 12,730 women dying because of the disease. A woman’s lifetime risk of developing ovarian cancer is approximately one in 91. Her lifetime risk of dying from ovarian cancer is approximately 1 in 143. Approximately half of the women diagnosed with ovarian cancer are 63 years or older. It is more prevalent in white women than in black women. As cancer care gets more customized, complete genetic profiling will become a critical component of cancer treatment delivery. Future uses will involve increased serial testing for resistance monitoring and tumor burden tracking across the treatment continuum.

On April 2025, leading precision oncology company Guardant Health, Inc. announced the release of Guardant360 Tissue, the first molecular profiling test for tumor tissue that combines extensive multiomics analysis, including genome-wide methylation data, DNA, RNA, and AI-powered PD-L1, to give researchers and cancer care teams a more complete picture of cancer. The sophisticated Guardant360 Tissue test, which is powered by the Guardant Infinity smart liquid biopsy platform, provides insights that are not usually possible with tests that do not include thorough epigenetic analysis.

Market Opportunity:

Advancements in Artificial Intelligence (AI) & cloud-based bioinformatics acts as opportunities for genomic cancer panel profiling market. The advancement of customized therapy is one of the most promising uses of AI in cancer genomics. For instance, AI can recommend the best targeted treatments based on the patient’s unique genomic changes, such as the existence of BRCA1/2 variations in breast cancer or EGFR mutations in non-small cell lung cancer, both of which can have a substantial impact on available treatments.

The development of predictive models that forecast how a patient’s tumor will react to medications or treatment plans is another crucial component of personalized medicine. By anticipating unfavorable medication reactions, these models can help prevent needless consequences and identify patients who can benefit from targeted medicines, immunotherapy, or chemotherapy.

On January 2024, PathAI, a global leader in AI-powered pathology, has announced the addition of six new oncology indications to PathExplore, the world’s first structured, standardized, and scalable panel for characterizing the tumor microenvironment (TME) from hematoxylin and eosin (H&E)-stained whole-slide images (WSIs). Additional indications include ovarian, bladder, liver, small cell lung, lymphoma, and head and neck cancer.

Recent Trends:

Emerging trends include expansion of liquid biopsy and ctDNA Profiling, ultra-low frequency mutation detection technologies, advancements in long-read sequencing, cloud-based bioinformatics workflows, and growth of companion diagnostics (CDx) co-development.

Liquid biopsy, specifically circulating tumor DNA (ctDNA) analysis, has emerged as a breakthrough technique in precision oncology, allowing for real-time, minimally invasive characterizations of the tumor and its dynamics. Compared to tissue biopsy, liquid biopsy has several advantages in the diagnosis and treatment of various types of cancer, such as being non-invasive and rapid. Currently, the use of liquid biopsy in tumor detection has garnered a lot of attention. It is already making remarkable progress, and it has enormous promise for future applications. Liquid biopsies include circulating tumor cells, circulating tumor DNA, exosomes, microRNA, circulating RNA, tumor platelets, and tumor endothelial cells. Furthermore, breakthroughs in the identification of liquid biopsy signs have considerably improved the feasibility of using liquid biopsies in clinical settings.

On November 2023, Illumina Inc., a global pioneer in DNA sequencing and array-based technologies, has introduced a new version of their distributed liquid biopsy assay for genomic profiling. The new TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that allows for noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not possible or to supplement tissue-based testing.

Restraints & Challenges:

Although the use of clinical tumor sequencing has enabled the identification of actionable genetic changes that may give molecular eligibility for matching targeted therapy, practical application and interpretation remain challenging. Some of the difficulties that restrict the potential of genomics-driven targeted therapies include intratumor heterogeneity, distinguishing between drivers and passenger mutations, lack of sustained response, and acquired resistance to targeted therapies. Although cancer genomics should be widely used as part of routine clinical care, some obstacles prevent its proper application and clinical implementation. Among the many problems, there is a widespread lack of understanding about when molecular profiling should be undertaken, what kind of assays should be utilized, and how the results should be interpreted for therapy selection.

Offering Segment Insights and Analysis:

Based on the offering segment, genomic cancer panel profiling market is segmented into instruments, kits and reagents, software/bioinformatics solutions, and services.

Instruments segment contributed the largest market share in 2024. Comprehensive genomic profiling (CGP) is ushering in a new era of precision medicine by allowing for more focused tumor treatment. Many CGP tests are not just for tissue samples. Some can be used to evaluate the tumor’s genetic signature in the blood, using sources like as cell-free DNA and circulating tumor DNA (ctDNA), allowing the malignancy to be identified. This is a simpler way to obtain tumor DNA and provides a more complete view of the tumor than taking a tiny biopsy from a heterogeneous tumor.

On May 2025, Illumina Inc. has announced an expansion of its clinical oncology portfolio, paving the way for the next generation of precision oncology solutions and improved patient care. The company’s diverse clinical offerings will make precision oncology more accessible to more cancer sufferers. Illumina TruSight (TSO) Comprehensive is the first and only FDA-approved test to provide a distributable comprehensive genomic profile IVD kit with pan-cancer CDx claims that assesses both DNA and RNA. This allows clinicians to rapidly match cancer patients with specific medicines based on thorough tumor profiling.

Technology Segment Insights and Analysis:

Based on the technology, genomic cancer panel profiling market is segmented into Next-Generation Sequencing (NGS), digital PCR / ddPCR, multiplex PCR & microarray, and others.

Next-Generation Sequencing (NGS) segment contributed the largest market share in 2024. Next-generation sequencing (NGS) has emerged as a game-changing tool in oncology, revolutionizing the way cancer is diagnosed and treated. NGS allows for precise genomic analysis of tumors, finding genetic abnormalities that drive cancer progression and permitting individualized therapy strategies that target specific mutations, thereby improving patient outcomes. This capability enables the creation of individualized treatment programs that target specific mutations, resulting in better patient outcomes and a better prognosis. Furthermore, the integration of NGS data with AI and machine learning (ML) is a promising development in oncology. These tools can examine enormous datasets to reveal patterns and relationships that would not be apparent using traditional methods. 

On April 2024, OGT, a leading global provider of genomic research and diagnostic solutions, has announced the release of the RNA-based SureSeq Myeloid Fusion Panel, a novel next-generation sequencing (NGS) tool for identifying important fusion genes involved in acute myeloid leukaemia. The SureSeq Myeloid Fusion Panel assures that results satisfy the most recent clinical research recommendations by effectively identifying over 30 important disease-associated fusions in AML, including KMT2A and MECOM fusions, in a single assay.

Clinical Application Segment Insights and Analysis:

Based on the clinical application, genomic cancer panel profiling market is segmented into companion diagnostics, diagnosis & tumor classification, immunotherapy response prediction, Minimal Residual Disease (MRD) monitoring, and clinical trials.

Diagnosis & tumor classification segment contributed the largest market share in 2024. Nucleic acid extraction, which includes both nucleic acid separation and purification, is an important step in many molecular biology clinical Applications, including PCR, sequencing, molecular cloning, and diagnostic testing. The rapid development of automated instruments has pushed laboratories to widely use magnetic bead–based nucleic acid extraction solutions in molecular diagnostics, especially nucleic acid detection, where these systems play a major role in enabling high-throughput automation.

The combination of personalized medicine and biomarker-guided therapy has caused a paradigm change in oncology, prompting the use of CGP in ordinary clinical practice. Furthermore, CGP provides a more efficient technique by employing frequently tiny amounts of available biopsy tissue, discovering gene fusions with unknown partners, assisting in the identification of carcinomas of unknown source, and facilitating the differential diagnosis of distinct malignancies.

On September 2024, Otsuka Pharmaceutical Co., Ltd., the National Cancer Center Japan, Kyushu University, Kyoto University, Nagoya Medical Center, Advanced Clinical Research Center, The Institute of Medical Science, and Keio University School of Medicine have announced that HemeSight, a hematological malignancies gene panel test, has been approved for manufacturing and marketing in Japan. The approval of the hematological malignancies gene panel test HemeSight is projected to significantly enhance personalized medicine in the field of hematopoietic oncology in Japan, resulting in better medical care.

Geographical Outlook:

Genomic cancer panel profiling market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Genomic Cancer Panel Profiling Market:

North America is registered to have highest market share in genomic cancer panel profiling market in 2024. Growing global cancer prevalence, the shift toward precision oncology and targeted therapies, and the rapid expansion of liquid biopsy and MRD testing primarily drive this market. The American Cancer Society reports that pancreatic cancer will affect an estimated 67,440 people in the United States in 2025 (34,950 men and 32,490 women), and it will cause 51,980 deaths (27,050 men and 24,930 women). The organization estimates that the average lifetime risk of developing pancreatic cancer is one in 56 for men and one in 60 for women.

Monitoring minimal residual disease (MRD) has become the standard of care for cancer detection around the world. MRD can be tested in a variety of ways, and the technique used is frequently determined by the lab where the test is performed. In the United States, the most common method for detecting MRD is flow cytometry: leukemia-associated immunophenotypes that are not found on normal hematopoietic cells are identified through a process of reacting live cells with inked antibodies that fluoresce when illuminated with a laser.

On April 2024, Nonacus, a genetic testing business, has introduced GALEASTM Tumor, a next generation sequencing (NGS) test that delivers thorough genomic profile of tumors, enabling doctors to precisely diagnose diseases and personalize treatments. The GALEAS Tumor test combines targeted NGS panels, custom bioinformatics for variant calling, and software for data analysis. GALEAS Tumor includes 519 genes involved with a variety of malignancies, including rare and complex cancers such brain tumors.

Asia Pacific Genomic Cancer Panel Profiling Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period, driven by shift toward precision oncology & targeted therapies, technological advancements in sequencing & bioinformatics, and growing burden of cancer globally. With Asia’s booming economies and rising incomes driving up healthcare spending, there is an increasing incentive for Asian governments, as well as local and Western companies, to conduct precision medicine research into diseases and conditions common in Asia. Major countries, such as China, India, and Japan, are increasingly adopting new healthcare technologies. And Asian governments are launching their own precision medicine efforts.

On September 2025, Lunit, a major provider of AI for cancer diagnostics and treatments, and Agilent Technologies Inc., a global leader in the life sciences, diagnostics, and applied chemical markets, have announced a nonexclusive agreement to provide AI-based companion diagnostic solutions. The collaboration will combine Lunit’s AI technology with Agilent’s expertise in tissue-based companion diagnostics to produce improved solutions that address the demand for novel and difficult biomarker assays in drug development.

Europe Genomic Cancer Panel Profiling Market:

Europe is expected to have considerable market share in 2024. Access to full genomic profiling in Europe is limited, with European cancer patients missing out on potentially life-saving targeted cancer treatments since present financing and reimbursement arrangements do not allow for routine testing for all relevant cancer mutations. Over the last decade, significant improvements have been made in genomic testing as well as the development of targeted medicines and immunotherapies for cancer patients, owing to a better understanding of cancer and the influence of each patient’s tumor’s unique genomic makeup.

For instance, on June 2023, the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), in collaboration with Exact Sciences, Guardant Health, Illumina, MSD, and Novartis, established the European Coalition for Access to Comprehensive Genomic Profiling (ECGP) to improve cancer care in Europe by increasing routine clinical access and reimbursement for Comprehensive Genomic Profiling (CGP). EUCOPE advocates for sound public policy that promotes innovation, while contributing to the Cancer Mission’s vision of improving the lives of more than three million by 2030.

Competition Analysis:

Genomic cancer panel profiling market is characterized by a fragmented structure, with several players competing across various segments and regions. List of major players included in genomic cancer panel profiling market report are:

• Illumina, Inc.
• Tempus
• Foundation Medicine, Inc.
• Medicover Genetics
• QIAGEN
• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• Hoffmann-La Roche Ltd
• Myriad Genetics, Inc.
• Exact Sciences Corporation
• Nonacus Limited
• Guardant Health
• NeoGenomics Laboratories
• Geneseeq Technology Inc.
• Paragon Genomics, Inc.

Strategic Developments in Genomic Cancer Panel Profiling Market:

• In October 2025, Circulogene has announced the nationwide launch of OncoGenDx, a novel tissue-based comprehensive genomic profiling (CGP) assay that provides new insights into all solid tumors. The new assay is intended to supplement Circulogene’s existing portfolio, which includes OncoGenLDx, the industry’s only plasma-based test that reports PD-L1 expression, and LungLifeAI, a targeted solution for risk stratifying incidental lung nodules. It reflects Circulogene’s ongoing commitment to advancing precision oncology with fast, modular, and clinically actionable testing options.
• In July 2025, NeoGenomics, Inc. has launched NEO PanTracer LBx, a blood-based complete genomic profiling (CGP) test, increasing its PanTracer portfolio. PanTracer LBx is a noninvasive test that supports therapy selection, trial matching, and longitudinal monitoring, allowing for data-driven decisions even when tumor tissue is limited or unavailable. PanTracer LBx uses circulating tumor DNA (ctDNA) from a simple blood draw to provide access to biomarker information when tissue samples are insufficient or unavailable. The test has a seven-day turnaround time and analyzes over 500 genes, including MSI and bTMB, to provide rapid, actionable results.
• In March 2025, GenomOncology, a precision medicine software company, has announced a strategic partnership with Chronetyx Laboratories, a leading provider of advanced diagnostic solutions. The collaboration will significantly reduce turnaround times for next-generation sequencing (NGS) testing results and streamline cancer care delivery. This collaboration combines GenomOncology’s Pathology Workbench with Chronetyx Laboratories’ NGS and information systems, specifically to support their FDA-cleared and CE-IVD-Marked Cyx Solid Tumor 505 test, allowing healthcare providers to receive critical genomic insights faster and make more timely treatment decisions.  The collaboration addresses a major issue in precision medicine: the time lag between sample collection and actionable outcomes.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of Genomic Cancer Panel Profiling Market Report:

Genomic Cancer Panel Profiling market report offers a detailed analysis of market size, including historical revenue (in USD Billion) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Offering Outlook (Revenue, USD Billion; 2022-2032)
  • Instruments
  • Kits and Reagents
  • Software/Bioinformatics Solutions
  • Services
• Technology Outlook (Revenue, USD Billion; 2022-2032)
  • Next-Generation Sequencing (NGS)
    1. Amplicon-based
    2. Hybrid capture-based
  • Digital PCR / ddPCR
  • Multiplex PCR & Microarray
  • Others
• Biomarker Type Outlook (Revenue, USD Billion; 2022-2032)
  • Single Nucleotide Variants (SNVs)
  • Copy Number Variants (CNVs)
  • Gene Fusions / Structural Variants
  • Tumor Mutational Burden (TMB)
  • Microsatellite Instability (MSI)
  • Others
• Clinical Application Outlook (Revenue, USD Billion; 2022-2032)
  • Companion Diagnostics
  • Diagnosis & Tumor Classification
  • Immunotherapy Response Prediction
  • Minimal Residual Disease (MRD) Monitoring
  • Clinical Trials
• Cancer Type Outlook (Revenue, USD Billion; 2022-2032)
  • Solid Tumors
    1. Lung
    2. Breast
    3. Colorectal
    4. Prostate
    5. Ovarian
    6. Pancreatic
    7. Others
  • Hematologic Malignancies
    1. Leukemia
    2. Lymphoma
    3. Multiple Myeloma
    4. Myelodysplastic Syndromes
  • End-Use Outlook (Revenue, USD Billion; 2022-2032)
    • Hospitals & Oncology Centers
    • Reference / Central Laboratories
    • Diagnostic Companies
    • Academic & Research Institutions
    • Pharmaceutical & Biotech Companies
    • CROs / Clinical Trial Labs
  • Regional Outlook (Revenue, USD Billion; 2022-2032)
    • North America
      1. S.
      2. Canada
      3. Mexico
    • Europe
      1. Germany
      2. France
      3. K.
      4. Italy
      5. Spain
      6. Benelux
      7. Nordic Countries
      8. Rest of Europe
    • Asia Pacific
      1. China
      2. India
      3. Japan
      4. South Korea
      5. Oceania
      6. ASEAN Countries
      7. Rest of APAC
    • Latin America
      1. Brazil
      2. Rest of LATAM
    • Middle East & Africa
      1. GCC Countries
      2. South Africa
      3. Israel
      4. Turkey
      5. Rest of MEA

Frequently Asked Questions (FAQ) about Genomic Cancer Panel Profiling market report